December 8, 2025Blood

Incidence of second primary malignancies (SPMs) following bispecific antibody (BsAb) therapy for lymphoid malignancies: A descriptive analysis of clinical trials

View Full Paper

Ask AI

Bookmark

Authors

THTalal HilalWinnMed

Discussion

Member takes

Implication

Descriptive analysis reveals low incidence of second primary malignancies in patients with hematologic malignancies treated with bispecific antibodies, suggesting ongoing monitoring is necessary.

Key Points

Cumulative incidence of second primary malignancies was 0.08 per 100 person-years in pooled analysis.
19 clinical trials included 5,133 patients, with median follow-up of 14.3 months reported.
Phase I-III trials evaluated several bispecific antibodies including blinatumomab and others.
Findings indicate a low incidence compared to CAR-T therapy but require long-term surveillance to clarify risks.

Cite This Study

Talal Hilal (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5d7 https://doi.org/10.1182/blood-2025-8071

View Full Paper

Ask AI

Bookmark

Implication

Descriptive analysis reveals low incidence of second primary malignancies in patients with hematologic malignancies treated with bispecific antibodies, suggesting ongoing monitoring is necessary.

Incidence of second primary malignancies (SPMs) following bispecific antibody (BsAb) therapy for lymphoid malignancies: A descriptive analysis of clinical trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Incidence of second primary malignancies (SPMs) following bispecific antibody (BsAb) therapy for lymphoid malignancies: A descriptive analysis of clinical trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider